Skip to main content
SpringerLink
Log in

Modelling the Anti-Migraine Effects of BIBN 4096 BS

A New Calcitonin Gene-Related Peptide Receptor Antagonist

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background and objective

Migraine attacks are associated with release of the calcitonin gene-related peptide (CGRP) from trigeminal nerves. BIBN 4096 BS is the first CGRP receptor antagonist tested in humans showing response rates similar to those reported for triptans, together with very good safety and tolerability profiles. The objective of the current study is to develop a population pharmacokinetic/pharmacodynamic model resembling the mechanism of action of BIBN 4096 BS, and to extract by model-based simulations dosage formulations and pharmacodynamic properties that can assist in the development of CGRP receptor antagonists.

Methods

126 patients with an acute moderate to severe migraine attack lasting not more than 6 hours were enrolled in this phase IIa study. BIBN 4096 BS was given as a single intravenous 10-minute infusion at different dose levels ranging from 0.25 to 10mg. Severity of headache was measured up to 24 hours. Patients who did not show pain relief by 2 hours were allowed to take rescue medication. Severity of headache and time to rescue medication measurements were fitted simultaneously using logistic regression and time-to-event analysis with nonlinear mixed-effect modelling software NONMEM version V.

Results

Severity of headache and time to rescue medication were described as a function of the fraction of the CGRP receptors blocked by BIBN 4096 BS, and controlled by the second- and first-order rate constants representing the onset (kon) and offset (koff) of the anti-migraine effects. The model predicted a slow rate of offset of the anti-migraine effect (half-life of koff = 21 hours). The model developed described the data well and was validated properly.

Discussion

A semi-mechanistic population pharmacokinetic/pharmacodynamic model has been developed for the anti-migraine effects of BIBN 4096 BS, characterised by the severity of headache and time to rescue medication. Simulations exploring the effect of the rate of absorption, bioavailability after an extravascular administration and the rate of activation/inactivation of the anti-migraine effect were performed. The rate of absorption seems to play a minor role; however, at least bioavailability fractions of 0.2–0.3 should be obtained. With regard to the kinetics of the anti-migraine effect, and to achieve a response rate of 60% at 2 hours, values of kon should be >0.081 mL/ng/h. At later times after administration higher values of koff are associated with faster offset of the response. The simulations showed that molecules with high kon and low koff values are the most promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Table II
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul–Aug; 41(7): 646–57

    Article  PubMed  CAS  Google Scholar 

  2. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive, peptide levels in the plasma of young migraine patients with or without aura assessed both interictally and ictally. Cephalalgia 1995 Oct; 15(5): 384–96

    PubMed  CAS  Google Scholar 

  3. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996 Aug; 16(5): 310–6

    Article  PubMed  CAS  Google Scholar 

  4. Durham PL. CGRP-receptor antagonists: a fresh approach to migraine therapy? N Engl J Med 2004 Mar; 350(11): 1073–5

    Article  PubMed  CAS  Google Scholar 

  5. Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagital sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991 Nov; 30(11): 1193–200

    Article  PubMed  CAS  Google Scholar 

  6. de Hoon JN, Willigers JM, Troost J, et al. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches. Clin Pharmacol Ther 2000 Oct; 68(4): 418–26

    Article  PubMed  Google Scholar 

  7. Schindler M, Doods HN. Binding properties of the novel, non-peptide CGRP receptor anatgonist radioligand, [(3)H] BIBN 4096 BS]. Eur J Pharmacol 2002 May; 442(3): 187–93

    Article  PubMed  CAS  Google Scholar 

  8. Doods H. Development of CGRP antagonists for the treatment of migraine. Curr Opin Investig Drugs 2001 Sep; 2(9): 1261–8

    PubMed  CAS  Google Scholar 

  9. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004 Mar; 350(11): 1104–10

    Article  PubMed  CAS  Google Scholar 

  10. Iovino M, Feifel U, Yong CL, et al. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia. 2004 Aug; 24(8): 645–56

    Article  PubMed  CAS  Google Scholar 

  11. Trocóniz IF, Wolters JM, Schaefer HG, et al. Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists. Eur J Pharm Sci 2004 Jul; 22(4): 287–95

    Article  PubMed  Google Scholar 

  12. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67–95

    Article  PubMed  CAS  Google Scholar 

  13. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1S–96S

    Google Scholar 

  14. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Stat Med 1995 May; 14(9–10): 911–22

    Article  PubMed  CAS  Google Scholar 

  15. Roon KI, Olesen J, Diener HC, et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000 Feb; 47(2): 238–41

    Article  PubMed  CAS  Google Scholar 

  16. Beal SL, Sheiner LB, editors. NONMEM users’ guides. San Francisco (CA): NONMEM Project Group, University of California at San Francisco, 1992

    Google Scholar 

  17. Sheiner LB. A new approach to the analysis of the analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther 1994 Sep; 56(3): 309–22

    Article  PubMed  CAS  Google Scholar 

  18. Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996 Dec; 60(6): 619–35

    Article  PubMed  CAS  Google Scholar 

  19. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992 Oct; 20(5): 511–28

    PubMed  CAS  Google Scholar 

  20. Jonsson EN, Karlsson MO. Xpose: an Splus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999 Jan; 58(1): 51–64

    Article  PubMed  CAS  Google Scholar 

  21. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to dtubocurarine. Clin Pharmacol Ther 1979 Mar; 25(3): 358–71

    PubMed  CAS  Google Scholar 

  22. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993 Aug; 21(4): 457–78

    PubMed  CAS  Google Scholar 

  23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001 Apr; 28(2): 171–92

    Article  PubMed  CAS  Google Scholar 

  24. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980

    Google Scholar 

  25. Visser SA, Huntjens DRH, Van der Graff PH, et al. Mechanism-based modeling of the pharmacodynamic intercation of alphaxalone and midazolam in rats. J Pharm Exp Ther 2003 Nov; 307(2): 765–75

    Article  CAS  Google Scholar 

  26. Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001 Aug; 18(8): 1210–9

    Article  PubMed  CAS  Google Scholar 

  27. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 1995 Feb; 23(1): 5–8

    PubMed  CAS  Google Scholar 

  28. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 1985 Jan; 37(1): 29–35

    Article  PubMed  CAS  Google Scholar 

  29. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003 Feb; 30(1): 83–103

    Article  PubMed  Google Scholar 

  30. Allen C, Jiang K, Malbecq W, et al. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalagia 1999 Jul; 19(6): 552–6

    Article  CAS  Google Scholar 

  31. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990 Sep; 30(3): 405–9

    Article  PubMed  CAS  Google Scholar 

  32. Troconiz IF, Armenteros S, Planelles MV, et al. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet 2000 Jun; 38(6): 505–18

    Article  PubMed  CAS  Google Scholar 

  33. Lindberg-Freijs A, Karlsson MO. Dose dependent absorption and linear disposition of cyclosporin A in rat. Biopharm Drug Dispos 1994 Jan; 15(1): 75–86

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach, Germany. Dr Iñaki F. Trocóniz has received research funding from Boehringer Ingelheim Pharma GmbH & Co. KG. Dr Jan-Markus Wolters, Christiane Tillmann, Dr Hans Guenter Schaefer, and Dr Willy Roth are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

Author information

Authors and Affiliations

  1. Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain

    Iñaki F. Trocóniz

  2. Department of Project Management R&D, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Strasse 65, Biberach, 88397, Germany

    Jan-Murkus Wolters

  3. Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany

    Christiane Tillmann, Hans G. Schaefer & Willy Roth

Authors
  1. Iñaki F. Trocóniz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan-Murkus Wolters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christiane Tillmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans G. Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Willy Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan-Murkus Wolters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trocóniz, I.F., Wolters, JM., Tillmann, C. et al. Modelling the Anti-Migraine Effects of BIBN 4096 BS. Clin Pharmacokinet 45, 715–728 (2006). https://doi.org/10.2165/00003088-200645070-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200645070-00006

Keywords

Search

Navigation